Senior Director, HEOR, Europe

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. As a new member of the Revolution Medicines team, you will join other outstanding Revolutionaries in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.

The Opportunity:

The Senior Director, HEOR, Europe will participate in developing the strategy and then driving execution of the tactical plan across health economics, outcomes research, and real-world evidence (RWE) to optimize the value demonstration of the Revolution Medicines oncology portfolio across European markets. They will work in concert with the Global HEOR and other regional teams to deliver an impa...